Ventura Capital has led the round for the Imperial College London-founded rapid covid-19 test kit maker, which will use the funding to expand internationally.
DNAnudge, a UK-based genetic testing technology provider exploiting research conducted at Imperial College London, has secured $60m in series A funding.
Investment firm Ventura Capital led the round, which included private banking group Julius Baer.
Founded in 2015, DNAnudge is developing DNA testing products that help users choose foods based on their genetic profiles, focusing on conditions including obesity, diabetes, hypertension and cholesterol.
The spinout will use the money to market globally its rapid RT-PCR test kit for Sars-Cov-2 called CovidNudge, which is already being used by the UK National Health Service’s hospitals.
Regius Prof Chris Toumazou, co-founder and CEO of DNAnudge, said: “The game-changing nature of our innovation has created an extraordinary commercial opportunity within next-generation medical diagnostics, and the global investor community is very excited by the transformative potential of a rapid, gold-standard RT-PCR testing platform that can screen for multiple viruses simultaneously.
“We are delighted to have completed this successful fundraise which will allow us to dramatically speed our plans for worldwide availability, particularly in the US, Japan, Europe and other key territories where interest is extremely high.”
